Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop
10.1038/onc.2012.513
Crossref journal-article
Springer Science and Business Media LLC
Oncogene (297)
Bibliography

Hayes, K. E., Walk, E. L., Ammer, A. G., Kelley, L. C., Martin, K. H., & Weed, S. A. (2012). Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene, 32(40), 4766–4777.

Authors 6
  1. K E Hayes (first)
  2. E L Walk (additional)
  3. A G Ammer (additional)
  4. L C Kelley (additional)
  5. K H Martin (additional)
  6. S A Weed (additional)
References 87 Referenced 37
  1. Pryor DI, Solomon B, Porceddu SV . The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol 2011; 7: 236–251. (10.1111/j.1743-7563.2011.01420.x) / Asia Pac J Clin Oncol by DI Pryor (2011)
  2. Leemans CR, Braakhuis BJ, Brakenhoff RH . The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9–22. (10.1038/nrc2982) / Nat Rev Cancer by CR Leemans (2011)
  3. Kalyankrishna S, Grandis JR . Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666–2672. (10.1200/JCO.2005.04.8306) / J Clin Oncol by S Kalyankrishna (2006)
  4. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14: 900–908. (10.1634/theoncologist.2009-0058) / Oncologist by T Hama (2009)
  5. Hama T, Yuza Y, Suda T, Saito Y, Norizoe C, Kato T et al. Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma. Clin Exp Metastasis 2012; 29: 19–25. (10.1007/s10585-011-9425-5) / Clin Exp Metastasis by T Hama (2012)
  6. Uribe P, Gonzalez S . Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathology - Research and Practice 2011 6/15 207: 337–342. / 6/15 by P Uribe (2011)
  7. Fung C, Grandis JR . Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010; 15: 355–373. (10.1517/14728214.2010.497754) / Expert Opin Emerg Drugs by C Fung (2010)
  8. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE . Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009; 11: 583–593. (10.1593/neo.09266) / Neoplasia by KG Neiva (2009)
  9. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14: 4284–4291. (10.1158/1078-0432.CCR-07-5226) / Clin Cancer Res by P Koppikar (2008)
  10. Yang JL, Qu XJ, Russell PJ, Goldstein D . Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett 2005; 225: 61–74. (10.1016/j.canlet.2004.11.041) / Cancer Lett by JL Yang (2005)
  11. Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC et al. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. Int J Cancer 2002; 99: 505–513. (10.1002/ijc.10373) / Int J Cancer by YT Huang (2002)
  12. Guarino M . Src signaling in cancer invasion. J Cell Physiol 2010; 223: 14–26. (10.1002/jcp.22011) / J Cell Physiol by M Guarino (2010)
  13. Kim LC, Song L, Haura EB . Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587–595. (10.1038/nrclinonc.2009.129) / Nat Rev Clin Oncol by LC Kim (2009)
  14. Summy JM, Gallick GE . Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337–358. (10.1023/A:1023772912750) / Cancer Metastasis Rev by JM Summy (2003)
  15. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67: 2800–2808. (10.1158/0008-5472.CAN-06-3469) / Cancer Res by AC Shor (2007)
  16. Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One 2011; 6: e28053. (10.1371/journal.pone.0028053) / PLoS One by YS Chen (2011)
  17. Johnson FM, Saigal B, Talpaz M, Donato NJ . Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11 (19 Pt 1): 6924–6932. (10.1158/1078-0432.CCR-05-0757) / Clin Cancer Res by FM Johnson (2005)
  18. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM . Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009; 69: 1958–1965. (10.1158/0008-5472.CAN-08-2944) / Cancer Res by B Sen (2009)
  19. Zhang S, Yu D . Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012, 3 33: 122–128. (10.1016/j.tips.2011.11.002) / Trends Pharmacol Sci by S Zhang (2012)
  20. Mayer EL, Krop IE . Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526–3532. (10.1158/1078-0432.CCR-09-1834) / Clin Cancer Res by EL Mayer (2010)
  21. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009; 8: 696–703. (10.4161/cbt.8.8.7903) / Cancer Biol Ther by DL Wheeler (2009)
  22. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1387–1394. (10.1200/JCO.2009.25.4029) / J Clin Oncol by EB Haura (2010)
  23. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118: 63–71. (10.1002/cncr.26204) / Cancer by JC Araujo (2012)
  24. Murphy DA, Courtneidge SA . The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011; 12: 413–426. (10.1038/nrm3141) / Nat Rev Mol Cell Biol by DA Murphy (2011)
  25. Linder S, Wiesner C, Himmel M . Degrading devices: invadosomes in proteolytic cell invasion. Annu Rev Cell Dev Biol 2011; 27: 185–211. (10.1146/annurev-cellbio-092910-154216) / Annu Rev Cell Dev Biol by S Linder (2011)
  26. Poincloux R, Lizarraga F, Chavrier P . Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009; 122 (Pt 17): 3015–3024. (10.1242/jcs.034561) / J Cell Sci by R Poincloux (2009)
  27. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC . Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006; 66: 3034–3043. (10.1158/0008-5472.CAN-05-2177) / Cancer Res by VV Artym (2006)
  28. Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X et al. Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol 2009; 186: 571–587. (10.1083/jcb.200812176) / J Cell Biol by M Oser (2009)
  29. Destaing O, Block MR, Planus E, Albiges-Rizo C . Invadosome regulation by adhesion signaling. Curr Opin Cell Biol 2011; 23: 597–606. (10.1016/j.ceb.2011.04.002) / Curr Opin Cell Biol by O Destaing (2011)
  30. Ren G, Crampton MS, Yap AS . Cortactin: Coordinating adhesion and the actin cytoskeleton at cellular protrusions. Cell Motil Cytoskeleton 2009; 66: 865–873. (10.1002/cm.20380) / Cell Motil Cytoskeleton by G Ren (2009)
  31. Buccione R, Caldieri G, Ayala I . Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev 2009; 28: 137–149. (10.1007/s10555-008-9176-1) / Cancer Metastasis Rev by R Buccione (2009)
  32. Kirkbride KC, Sung BH, Sinha S, Weaver AM . Cortactin: a multifunctional regulator of cellular invasiveness. Cell Adh Migr 2011, Mar-Apr 5: 187–198. (10.4161/cam.5.2.14773) / Cell Adh Migr by KC Kirkbride (2011)
  33. Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT et al. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 2001; 11: 370–374. (10.1016/S0960-9822(01)00098-7) / Curr Biol by AM Weaver (2001)
  34. Ammer AG, Weed SA . Cortactin branches out: roles in regulating protrusive actin dynamics. Cell Motil Cytoskeleton 2008; 65: 687–707. (10.1002/cm.20296) / Cell Motil Cytoskeleton by AG Ammer (2008)
  35. Martinez-Quiles N, Ho HY, Kirschner MW, Ramesh N, Geha RS . Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Mol Cell Biol 2004; 24: 5269–5280. (10.1128/MCB.24.12.5269-5280.2004) / Mol Cell Biol by N Martinez-Quiles (2004)
  36. Kelley LC, Ammer AG, Hayes KE, Martin KH, Machida K, Jia L et al. Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation. J Cell Sci 2010; 123 (Pt 22): 3923–3932. (10.1242/jcs.075200) / J Cell Sci by LC Kelley (2010)
  37. Oser M, Mader CC, Gil-Henn H, Magalhaes M, Bravo-Cordero JJ, Koleske AJ et al. Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia. J Cell Sci 2010; 123 (Pt 21): 3662–3673. (10.1242/jcs.068163) / J Cell Sci by M Oser (2010)
  38. Tehrani S, Tomasevic N, Weed S, Sakowicz R, Cooper JA . Src phosphorylation of cortactin enhances actin assembly. Proc Natl Acad Sci USA 2007; 104: 11933–11938. (10.1073/pnas.0701077104) / Proc Natl Acad Sci USA by S Tehrani (2007)
  39. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 2005; 168: 441–452. (10.1083/jcb.200407076) / J Cell Biol by H Yamaguchi (2005)
  40. Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete S, Luini A et al. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci 2008; 121 (Pt 3): 369–378. (10.1242/jcs.008037) / J Cell Sci by I Ayala (2008)
  41. Webb BA, Jia L, Eves R, Mak AS . Dissecting the functional domain requirements of cortactin in invadopodia formation. Eur J Cell Biol 2007; 86: 189–206. (10.1016/j.ejcb.2007.01.003) / Eur J Cell Biol by BA Webb (2007)
  42. Colicelli J . ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 2010; 3: re6. (10.1126/scisignal.3139re6) / Sci Signal by J Colicelli (2010)
  43. Bradley WD, Koleske AJ . Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci 2009; 122 (Pt 19): 3441–3454. (10.1242/jcs.039859) / J Cell Sci by WD Bradley (2009)
  44. Plattner R, Pendergast AM . Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle 2003, Jul-Aug 2: 273–274. (10.4161/cc.2.4.409) / Cell Cycle by R Plattner (2003)
  45. Ernst T, Hochhaus A . Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012; 39: 58–66. (10.1053/j.seminoncol.2011.11.002) / Semin Oncol by T Ernst (2012)
  46. Wang Y, Gu M, Mi Y, Qiu L, Bian S, Wang J . Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult. Int J Hematol 2011; 94: 552–555. (10.1007/s12185-011-0953-1) / Int J Hematol by Y Wang (2011)
  47. Srinivasan D, Plattner R . Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648–5655. (10.1158/0008-5472.CAN-06-0734) / Cancer Res by D Srinivasan (2006)
  48. Srinivasan D, Sims JT, Plattner R . Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095–1105. (10.1038/sj.onc.1210714) / Oncogene by D Srinivasan (2008)
  49. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007; 26: 6989–6996. (10.1038/sj.onc.1210500) / Oncogene by J Lin (2007)
  50. Furlan A, Stagni V, Hussain A, Richelme S, Conti F, Prodosmo A et al. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ 2011; 18: 1608–1616. (10.1038/cdd.2011.23) / Cell Death Differ by A Furlan (2011)
  51. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 2011; 71: 1730–1741. (10.1158/0008-5472.CAN-10-1432) / Cancer Res by CC Mader (2011)
  52. Lapetina S, Mader CC, Machida K, Mayer BJ, Koleske AJ . Arg interacts with cortactin to promote adhesion-dependent cell edge protrusion. J Cell Biol 2009; 185: 503–519. (10.1083/jcb.200809085) / J Cell Biol by S Lapetina (2009)
  53. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 2011; Sep: 5. / Oncogene by SS Ganguly (2011)
  54. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM . c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400–2411. (10.1101/gad.13.18.2400) / Genes Dev by R Plattner (1999)
  55. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM . Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem 2010; 285: 40201–40211. (10.1074/jbc.M110.147330) / J Biol Chem by PS Smith-Pearson (2010)
  56. Sibony-Benyamini H, Gil-Henn H . Invadopodia: the leading force. Eur J Cell Biol 2012; 91: 896–901. (10.1016/j.ejcb.2012.04.001) / Eur J Cell Biol by H Sibony-Benyamini (2012)
  57. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM et al. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 2011; 6: 2104–2111. (10.1097/JTO.0b013e31822e7256) / J Thorac Oncol by AS Tsao (2011)
  58. Clark ES, Whigham AS, Yarbrough WG, Weaver AM . Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007; 67: 4227–4235. (10.1158/0008-5472.CAN-06-3928) / Cancer Res by ES Clark (2007)
  59. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000; 20: 9018–9027. (10.1128/MCB.20.23.9018-9027.2000) / Mol Cell Biol by RA Blake (2000)
  60. Johnson FM, Saigal B, Donato NJ . Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol 2005; 205: 218–227. (10.1002/jcp.20383) / J Cell Physiol by FM Johnson (2005)
  61. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006; 49: 6465–6488. (10.1021/jm060434q) / J Med Chem by LF Hennequin (2006)
  62. Summy JM, Gallick GE . Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12: 1398–1401. (10.1158/1078-0432.CCR-05-2692) / Clin Cancer Res by JM Summy (2006)
  63. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006; 66: 8017–8025. (10.1158/0008-5472.CAN-05-4490) / Cancer Res by BL Rothschild (2006)
  64. Noren NK, Foos G, Hauser CA, Pasquale EB . The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006; 8: 815–825. (10.1038/ncb1438) / Nat Cell Biol by NK Noren (2006)
  65. Allington TM, Galliher-Beckley AJ, Schiemann WP . Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J 2009; 23: 4231–4243. (10.1096/fj.09-138412) / FASEB J by TM Allington (2009)
  66. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY . Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 2001; 20: 3845–3856. (10.1038/sj.onc.1204531) / Oncogene by F Frasca (2001)
  67. Huang C, Liu J, Haudenschild CC, Zhan X . The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998; 273: 25770–25776. (10.1074/jbc.273.40.25770) / J Biol Chem by C Huang (1998)
  68. Boyle SN, Michaud GA, Schweitzer B, Predki PF, Koleske AJ . A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave formation. Curr Biol 2007; 17: 445–451. (10.1016/j.cub.2007.01.057) / Curr Biol by SN Boyle (2007)
  69. Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM . Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004; 24: 2573–2583. (10.1128/MCB.24.6.2573-2583.2004) / Mol Cell Biol by R Plattner (2004)
  70. Head JA, Jiang D, Li M, Zorn LJ, Schaefer EM, Parsons JT et al. Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. Mol Biol Cell 2003; 14: 3216–3229. (10.1091/mbc.e02-11-0753) / Mol Biol Cell by JA Head (2003)
  71. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA . Cortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence. PLoS One 2010; 5: e13847. (10.1371/journal.pone.0013847) / PLoS One by LC Kelley (2010)
  72. O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA . Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000; 60: 1121–1128. / Cancer Res by P O-charoenrat (2000)
  73. Ohnishi Y, Inoue H, Furukawa M, Kakudo K, Nozaki M . Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. Oncol Rep 2012; 27: 954–958. (10.3892/or.2011.1616) / Oncol Rep by Y Ohnishi (2012)
  74. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther 2009; 1: 52–61. (10.4172/1948-5956.1000009) / J Cancer Sci Ther by AG Ammer (2009)
  75. Liberatore RA, Goff SP, Nunes I . NF-kappaB activity is constitutively elevated in c-Abl null fibroblasts. Proc Natl Acad Sci USA 2009; 106: 17823–17828. (10.1073/pnas.0905935106) / Proc Natl Acad Sci USA by RA Liberatore (2009)
  76. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC et al. like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007; 26: 2006–2016. (10.1038/sj.onc.1209999) / Oncogene by F Wang (2007)
  77. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010; 5: e12702. (10.1371/journal.pone.0012702) / PLoS One by H Hatakeyama (2010)
  78. Yanagawa T, Harada H, Iwasa S, Tabuchi K, Omura K, Suzuki H et al. c-Abl expression in oral squamous cell carcinomas. Oral Oncol 2000; 36: 89–94. (10.1016/S1368-8375(99)00067-6) / Oral Oncol by T Yanagawa (2000)
  79. Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 2011; 31: 249–253. / Anticancer Res by MG Fury (2011)
  80. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011; 117: 2112–2119. (10.1002/cncr.25769) / Cancer by HD Brooks (2011)
  81. Montero JC, Seoane S, Ocana A, Pandiella A . Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546–5552. (10.1158/1078-0432.CCR-10-2616) / Clin Cancer Res by JC Montero (2011)
  82. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 179–184. (10.1097/CAD.0b013e328325a867) / Anticancer Drugs by PN Lara (2009)
  83. Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 2011; 11: 306–311. (10.1016/j.clbc.2011.03.021) / Clin Breast Cancer by A Gucalp (2011)
  84. Cai L, Makhov AM, Schafer DA, Bear JE . Coronin 1B antagonizes cortactin and remodels Arp2/3-containing actin branches in lamellipodia. Cell 2008; 134: 828–842. (10.1016/j.cell.2008.06.054) / Cell by L Cai (2008)
  85. Poppe M, Feller SM, Romer G, Wessler S . Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility. Oncogene 2007; 26: 3462–3472. (10.1038/sj.onc.1210139) / Oncogene by M Poppe (2007)
  86. Antoku S, Saksela K, Rivera GM, Mayer BJ . A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors. J Cell Sci 2008; 121 (Pt 18): 3071–3082. (10.1242/jcs.031575) / J Cell Sci by S Antoku (2008)
  87. Martin KH, Hayes KE, Walk EL, Ammer AG, Markwell SM, Weed SA . Quantitative measurement of invadopodia-mediated extracellular matrix proteolysis in single and multicellular contexts. J Vis Exp 2012; 66: e4119. / J Vis Exp by KH Martin (2012)
Dates
Type When
Created 12 years, 9 months ago (Nov. 12, 2012, 4:51 p.m.)
Deposited 1 year, 4 months ago (May 1, 2024, 5:23 a.m.)
Indexed 2 months ago (July 2, 2025, 12:32 a.m.)
Issued 12 years, 9 months ago (Nov. 12, 2012)
Published 12 years, 9 months ago (Nov. 12, 2012)
Published Online 12 years, 9 months ago (Nov. 12, 2012)
Published Print 11 years, 11 months ago (Oct. 1, 2013)
Funders 0

None

@article{Hayes_2012, title={Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop}, volume={32}, ISSN={1476-5594}, url={http://dx.doi.org/10.1038/onc.2012.513}, DOI={10.1038/onc.2012.513}, number={40}, journal={Oncogene}, publisher={Springer Science and Business Media LLC}, author={Hayes, K E and Walk, E L and Ammer, A G and Kelley, L C and Martin, K H and Weed, S A}, year={2012}, month=nov, pages={4766–4777} }